These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Emergency coronary artery bypass grafting in patients with acute myocardial infarction treated with glycoprotein IIb/IIIa receptor inhibitors. De Carlo M; Maselli D; Cortese B; Ciabatti N; Gistri R; Levantino M; Balbarini A; De Caterina R; Petronio AS Int J Cardiol; 2008 Jan; 123(3):229-33. PubMed ID: 17433463 [TBL] [Abstract][Full Text] [Related]
4. Platelet receptor glycoprotein IIb/IIIa inhibition with eptifibatide in a patient with thrombocytopenia after treatment with abciximab. Coto H J Invasive Cardiol; 2000 Oct; 12(10):528-31. PubMed ID: 11022214 [TBL] [Abstract][Full Text] [Related]
5. Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: IIb or Not IIb, what is the question? Young JJ; Kereiakes DJ J Invasive Cardiol; 2002 Jul; 14(7):404-10. PubMed ID: 12082194 [TBL] [Abstract][Full Text] [Related]
6. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors. Dunn A Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344 [No Abstract] [Full Text] [Related]
7. [Impact of GP IIb/IIIa antagonists in interventional cardiology]. Scheller B; Hennen B; Böhm M; Nickenig G Dtsch Med Wochenschr; 2003 Feb; 128(6):281-7. PubMed ID: 12571800 [No Abstract] [Full Text] [Related]
9. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis. Glaser R; Glick HA; Herrmann HC; Kimmel SE J Am Coll Cardiol; 2006 Feb; 47(3):529-37. PubMed ID: 16458131 [TBL] [Abstract][Full Text] [Related]
10. Effects of glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel: a meta-analysis of randomized trials. Pannu R; Andraws R Crit Pathw Cardiol; 2008 Mar; 7(1):5-10. PubMed ID: 18458661 [TBL] [Abstract][Full Text] [Related]
11. Abciximab: a review and update for clinicians. Mazzaferri EL; Young JJ Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):609-18. PubMed ID: 18510478 [TBL] [Abstract][Full Text] [Related]
12. Intravenous versus intracoronary bolus of glycoprotein IIb/IIIa inhibitor administration during primary percutaneous coronary intervention on long-term left ventricular systolic and diastolic function. Pellicori P; Torromeo C; Barillà F; Mangieri E; Evangelista A; Truscelli G; Costanzo P; Hoye A; Wong K Cardiol J; 2013; 20(3):310-7. PubMed ID: 23788306 [TBL] [Abstract][Full Text] [Related]
13. Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition? Tcheng JE; Campbell ME J Am Coll Cardiol; 2003 Oct; 42(7):1196-8. PubMed ID: 14522479 [No Abstract] [Full Text] [Related]
18. Platelet glycoprotein IIb/IIIa receptor inhibitors--end of an era? Roffi M; Mukherjee D Eur Heart J; 2008 Feb; 29(4):429-31. PubMed ID: 18276614 [No Abstract] [Full Text] [Related]
19. Comparison between glycoprotein IIb/IIIa blockade and distal protection device for the restoration of myocardial perfusion during percutaneous coronary intervention for acute myocardial infarction. Mak KH; Phay C; Wong A; Kwok V; Tan KS; Lau KW; Koh TH J Invasive Cardiol; 2004 Dec; 16(12):694-8. PubMed ID: 15596872 [TBL] [Abstract][Full Text] [Related]
20. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial. Marmur JD; Mitre CA; Barnathan E; Cavusoglu E Am Heart J; 2006 Nov; 152(5):876-81. PubMed ID: 17070148 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]